Optimizing hypoxia detection and treatment strategies

Seminars in Nuclear Medicine

Volumn 45, Issue 2, 2015, Pages 163-176

  Koch, Cameron J ^a   Evans, Sydney M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1,1,1,3,3,3 HEXAFLUORO 2 PROPOXY) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 NITROIMIDAZOLE; DOXORUBICIN; DYE; EF 3; ETANIDAZOLE; HOE 33342; MISONIDAZOLE; NITROREDUCTASE; OXYGEN; PIMONIDAZOLE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; ESOPHAGUS CANCER; HUMAN; HYPOXIA; IMAGE GUIDED RADIOTHERAPY; IMMUNOHISTOCHEMISTRY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SARCOMA; THERAPY EFFECT; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; ANIMAL; CELL HYPOXIA; CLINICAL TRIAL (TOPIC); METABOLISM; MOLECULAR IMAGING; NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR IMAGING; NEOPLASMS; NITROREDUCTASES;

EID: 84924027806     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2014.10.004     Document Type: Review

References (94)

1. S.M. Evans, A. Schrlau, and A.A. Chalian Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding J Invest Dermatol 126 2006 2596 2606
2. S.W. Tuttle, A. Maity, and P.R. Oprysko Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration: Implications for HIF-1 stability under moderate hypoxia J Biol Chem 282 2007 36790 36796
3. C.J. Koch Competition between radiation protectors and radiation sensitizers in mammalian cells O.F. Nygaard, M.G. Simic, Radioprotectors and Anticarcinogens 1983 Academic press New York 275 296
4. R.H. Thomlinson, and L.H. Gray The histological structure of some human lung cancers and the possible implications for radiotherapy Br J Cancer 9 1955 539 579
5. A.J. Varghese, and G.F. Whitmore Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole Cancer Res 40 1980 2165 2169
6. P. Wardman Molecular structure and biological activity of hypoxic cell radiosensitizers and hypoxic specific cytotoxins A. Breccia, C. Rimondi, G.E. Adams, Advanced Topics on Radiosensitizers of Hypoxic Cells 1982 Plenum Press New York 49 75
7. C.N. Coleman, T.H. Wasserman, and R.C. Urtasun Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03 Int J Radiat Oncol Biol Phys 18 1990 389 393
8. S. Dische Chemical sensitizers for hypoxic cells: A decade of experience in clinical radiotherapy Radiother Oncol 3 1985 97 115
9. 2 predicts survival in advanced cancer of the uterine cervix Radiother Oncol 26 1993 45 50
10. M. Hockel, K. Schlenger, and B. Aral Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res 56 1996 4509 4515
11. D.M. Brizel, S.P. Scully, and J.M. Harrelson Tissue oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma Cancer Res 56 1996 941 943
12. A.W. Fyles, M. Milosevic, and R. Wong Oxygenation predicts radiation response and survival in patients with cervix cancer Radiother Oncol 48 1998 149 156
13. H.B. Stone, J.M. Brown, and T.L. Phillips Oxygen in human tumors: Correlations between methods of measurement and response to therapy Radiat Res 136 1993 422 434
14. M. Nordsmark, S.O. Bentzen, and V. Rudat Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study Radiother Oncol 77 2005 18 24
15. M. Nordsmark, J. Loncaster, and C. Aquino-Parsons Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas Radiother Oncol 67 2003 35 44
16. J.M. Brown Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation Br J Radiol 52 1979 650 656
17. D.J. Chaplin, R.E. Durand, and P.L. Olive Acute hypoxia in tumors: Implications for modifiers of radiation effects Int J Radiat Biol Phys 12 1986 1279 1282
18. D.J. Chaplin, P.L. Olive, and R.E. Durand Intermittent blood flow in a murine tumor: Radiobiological effects Cancer Res 47 1987 597
19. M.J. Trotter, and P.L. Olive Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse Br J Cancer 62 1990 903 908
20. C.J. Koch, W.T. Jenkins, and K.W. Jenkins Mechanisms of blood flow and hypoxia production in rat 9L-epigastric tumors Tumor Microenviron Ther 1 2012 1 13
21. S.M. Evans, S. Hahn, and D.R. Pook Hypoxia in human intraperitoneal and extremity sarcomas Int J Radiat Oncol Biol Phys 49 2000 587 596
22. S.M. Evans, K.W. Jenkins, and H.I. Chen The relationship between hypoxia, proliferation and outcome in patients with de novo glioblastoma: A pilot study Transl Oncol 3 2010 160 169
23. 2 gradients in window chamber tumours: Impact on tumour hypoxia Br J Cancer 79 1999 1717 1722
24. S.M. Evans, C.J. Koch, and B. Joiner Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide] Br J Cancer 72 1995 875 882
25. 18F-EF5 to immunohistochemical marker EF5 in 3 different human tumor xenograft models J Nucl Med 55 2014 1192 1197
26. C.J. Koch Measurement of Absolute oxygen levels in cells and tissues using oxygen sensors and the 2-nitroimidazole EF5 Methods Enzymol 353 2002 3 31
27. D.M. Aebersold, P. Burri, and K.T. Beer Expression of hypoxia-inducible factor-1α: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer Cancer Res 61 2001 2911 2916
28. N. Vahidi, R.B. Clarkson, and K.J. Liu In vivo and in vitro EPR oximetry with fusinite: A new coal-derived, particulate EPR probe Magn Reson Med 31 1994 139 146
29. H. Yasui, S. Matsumoto, and N. Devasahayam Low field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice Cancer Res 15 2010 6427 6436
30. C.J. Koch, and S.M. Evans Non-invasive imaging of hypoxia - Challenges and opportunities X. Chen, Molecular Imaging Probes for Cancer Research 2010 World Scientific New Jersey 285 313 ([Chapter 10])
31. J. Overgaard, H.S. Hansen, and M. Overgaard A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 Radiother Oncol 46 1998 135 146
32. J.E. Mohindra, and A.M. Rauth Increased killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells Cancer Res 36 1976 930 936
33. R. Sridhar, C.J. Koch, and R.M. Sutherland Cytotoxicity of two nitroimidazole radiosensitizers in an in vitro tumor model Int J Radiat Oncol Biol Phys 1 1976 1149 1157
34. A.J. Varghese, S. Gulyas, and J.K. Mohindra Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo Cancer Res 36 1976 3761 3765
35. J.D. Chapman Hypoxic sensitizers - Implications for radiation therapy New Engl J Med 301 1979 1429 1432
36. 99mTc]HL-91: Correlation with microelectrode measurements J Nucl Med 42 2001 337 344
37. K.A. Krohn, J.M. Link, and R.P. Mason Molecular imaging of hypoxia J Nucl Med 49 2008 129S 148S
38. G.G. Miller, M.W. Best, and A.J. Franko Quantitation of hypoxia in multicellular spheroids by video image analysis Int J Radiat Oncol Biol Phys 16 1989 949 952
39. R.J. Hodgkiss, G. Jones, and A. Long Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection Br J Cancer 63 1991 119 125
40. E.M. Lord, L.W. Harwell, and C.J. Koch Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts Cancer Res 53 1993 5271 5276
41. M.A. Varia, D.P. Calkins-Adams, and L.H. Rinker Pimonidazole: A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma Gynecol Oncol 71 1998 270 277
42. 18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure Appl Radiat Isot 54 2001 73 80
43. O. Josse, D. Labar, and B. Georges Synthesis of [F-18]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia Bioorg Med Chem 9 2001 665 675
44. 18F-fluoromisonidazole Semin Nucl Med 37 2007 451 461
45. J.R. Ballinger Imaging hypoxia in tumors Semin Nucl Med 31 2001 321 329
46. M.R. Horsman, L.S. Mortensen, and J.B. Petersen Imaging hypoxia to improve radiotherapy outcome Nat Rev Clin Oncol 9 2012 674 687
47. C.J. Koch The reductive activation of nitroimidazoles; modification by oxygen and other redox-active molecules in cellular systems G.E. Adams, A. Breccia, E.M. Fielden, Selective Activation of Drugs by Redox Processes. NATO Series A 198 1990 Plenum Press New York 237 247
48. Chapman JD, Lee J, Meeker BE: Adduct formation by 2-nitroimidazole drugs in mammalian cells: Optimization of markers for tissue oxygenation. In: Adams GE, Breccia A, Fielden EM, et al.,(eds): Selective Activation of Drugs by Redox Processes. NATO Series A, New York: Plenum Press; 1990;198:313-323
49. C.J. Koch, S.M. Evans, and E.M. Lord Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity Br J Cancer 72 1995 869 874
50. C.J. Koch Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole Radiat Res 169 2008 677 688
51. W.R. Wilson, and M.P. Hay Targeting hypoxia in cancer therapy Nat Rev Cancer 11 2011 393 410
52. C.P. Guise, M.R. Abbattista, and R.S. Singleton The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3 Cancer Res 70 2010 1573 1584
53. M. Busk, M.R. Horsman, and S. Jakobsen Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage Eur J Nucl Med Mol Imaging 35 2008 2294 2303
54. C.J. Koch A thin-film culturing technique allowing rapid gas-liquid equilibration (6 seconds) with no toxicity to mammalian cells Radiat Res 97 1984 434 442
55. C.P. Guise, M.R. Abbattista, and S.R. Tipparaju Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia Mol Pharmacol 81 2012 31 40
56. G.A. Prosser, J.N. Copp, and S.P. Syddall Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954 Biochem Pharmacol 79 2010 678 687
57. J.A. Raleigh, and C.J. Koch The importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules Biochem Pharmacol 40 1990 2457 2464
58. C.J. Koch, and J.A. Raleigh Radiolytic reduction of protein and non-protein disulfides in the presence of formate: A chain reaction Arch Biochem Biophys 287 1991 75 84
59. R.A. McClelland, R. Panicucci, and A.M. Rauth Products of the reductions of 2-nitroimidazoles J Am Chem Soc 109 1987 4308 4314
60. 14C-misonidazole to hypoxic cells: Kinetic dependence on oxygen concentration and misonidazole concentration Int J Radiat Oncol Biol Phys 10 1984 1327 1332
61. K.M. Laughlin, S.M. Evans, and W.T. Jenkins Biodistribution of the nitroimidazole EF5 [2-(2-nitro-1H-imidazole-1yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide] in mice bearing subcutaneous EMT6 tumors J Pharmacol Exp Ther 277 1996 1049 1057
62. S.M. Evans, and C.J. Koch Prognostic significance of tumor oxygenation in humans Cancer Lett 195 2003 1 16
63. J. Wang, A. Foehrenbacher, and J. Su The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia Clin Cancer Res 18 2012 1684 1695
64. 18F]fluoromisonidazole: A pretherapy study of 37 patients Int J Radiat Oncol Biol Phys 36 1996 417 428
65. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer BMC Cancer 5 2005 152
66. 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer EJNMMI Res 3 2013 42
67. P. Workman Pharmacokinetics of hypoxic cell radiosensitizers Cancer Clin Trials 3 1980 237 251
68. G. Mees, A. Maes, and M. Sathekge Radiolabelled probes targeting tumor hypoxia for personalized medicine Curr Pharm Des 20 2014 2308 23018
69. J.J. Cascieri, M.M. Graham, and J.S. Rasey A modelling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data Med Phys 22 1995 1127 1139
70. S. Carlin, and J.L. Humm PET of hypoxia: Current and future perspectives J Nucl Med 53 2012 1171 1174
71. K.O. Hicks, Y. Fleming, and B.G. Siim Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model Int J Radiat Oncol Biol Phys 42 1998 641 649
72. R.M. Sutherland Cell and environmental interactions in tumor microregions: The multicellular spheroid model Science 240 1988 177 184
73. 18F]FETNIM: A potential marker for PET J Nucl Med 42 2001 1397 1404
74. C.J. Koch, S.M. Hahn, and K.J. Rockwell Pharmacokinetics of the 2-nitroimidazole EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide] in human patients: Implications for hypoxia measurements in vivo Cancer Chemother Pharmacol 48 2001 177 187
75. 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer J Nucl Med 49 2008 1 8
76. K. Lehtio, O. Eskola, and T. Viljanen Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer Int J Radiat Oncol Biol Phys 35 2004 975 980
77. L.I. Cardenas-Navia, D. Mace, and R.A. Richardson The pervasive presence of fluctuating oxygenation in tumors Cancer Res 68 2008 5812 5819
78. E.K. Rofstad, J.V. Gaustad, and T.A.M. Egeland Tumors exposed to acute cycling hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination Int J Cancer 127 2010 1535 1546
79. S.M. Evans, S. Hahn, and D.R. Pook Detection of hypoxia in human squamous cell carcinoma by EF5 binding Cancer Res 60 2000 2018 2024
80. S.M. Evans, D.L. Fraker, and S.M. Hahn EF5 binding and clinical outcome in human soft tissue sarcomas Int J Radiat Oncol Biol Phys 64 2006 922 927
81. D.M. Brizel, G.S. Sibley, and L.R. Prosnitz Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck Int J Radiat Oncol Biol Phys 38 1997 285 289
82. 18F-FETNIM in esophageal squamous cell carcinoma: A pilot clinical study Dis Esophagus 25 2012 54 61
83. L.S. Mortensen, J. Johansen, and J. Kallehauge FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the Dahanca 24 trial Radiother Oncol 105 2012 14 20
84. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2006 2098 2104
85. J.M. Brown, and A.J. Giaccia The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy Cancer Res 58 1998 1408 1416
86. J.M. Brown Imaging tumor sensitivity to a bioreductive prodrug: Two for the price of one! Clin Cancer Res 18 2012 1487 1489
87. C.J. Koch The unusual dependence on oxygen concentration of toxicity by SR-4233 [3-amino-1,2,4-benzotriazine-1,4-dioxide]: An hypoxic cell toxin Cancer Res 53 1993 3992 3997
88. D. Rischin, L. Peters, and R. Hicks Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer J Clin Oncol 19 2001 535 542
89. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model J Nucl Med 54 2013 1339 1346
90. A.G. Gupta, J.H. Lee, and W.W. Wilke Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-infected cell line and relationship to signalling through AKT Int J Radiat Oncol Biol Phys 74 2009 928 933
91. C.C. Ling, J. Humm, and S. Larson Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality Int J Radiat Oncol Biol Phys 47 2000 551 560
92. A.-L. Grosu, M. Souvatzoglou, and B. Roper Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer Int J Radiat Oncol Biol Phys 69 2007 541 551
93. K.S. Chao, W.R. Bosch, and S. Mutic A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy Int J Radiat Oncol Biol Phys 49 2001 1171 1182
94. R.T. Flynn, S.R. Bowen, and S.M. Bentzen Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting Phys Med Biol 53 2008 4153 4167